Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
1. LLY stock fell 14% due to negative drug trial data. 2. Positive trial results led to a 6% recovery in stock price. 3. Orforglipron's approval could transform obesity treatment globally. 4. Strong Q2 earnings show significant revenue growth for LLY. 5. Insider purchasing signals potential bullish sentiment despite pricing pressures.